The Centers for Medicare & Medicaid Services (CMS) is expanding Medicare coverage for genetic testing through the MolDX program administered by Palmetto GBA.
CMS announced two new local coverage determinations (LCDs) to cover diagnostic tests used to evaluate and manage care for patients suspected of having hereditary transthyretin amyloidosis:
The LCDs will take effect Aug. 17 in 23 states.
Source:
https://www.cap.org/advocacy/latest-news-and-practice-data/july-8-2025
The American Medical Association and 111 specialty societies and state medical associations are urging administration officials to implement strong...
Lincoln, NE – April 2026 TELCOR is proud to announce the promotion Alexis Determan to Senior Implementation Analyst, RCM and Alyson Lyon to Technical...
Virginia Gov. Abigail Spanberger signed Senate Bill 745 on April 6, prohibiting health plans from imposing unnecessary restrictions on referrals to...